PRQR Stock Overview
ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
NewNotes are coming soon
ProQR Therapeutics N.V. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.15 |
| 52 Week High | US$6.15 |
| 52 Week Low | US$0.53 |
| Beta | 0.22 |
| 1 Month Change | -11.76% |
| 3 Month Change | 240.91% |
| 1 Year Change | -46.97% |
| 3 Year Change | -62.54% |
| 5 Year Change | 4.13% |
| Change since IPO | -78.62% |
Recent News & Updates
Recent updates
ProQR says EU regulator seeks additional trial for lead candidate
Aug 11Here's Why ProQR Therapeutics (NASDAQ:PRQR) Can Manage Its Debt Despite Losing Money
Nov 10
Investment Case On ProQR Therapeutics Gets More Enticing
Oct 01ProQR Therapeutics (NASDAQ:PRQR) Has Debt But No Earnings; Should You Worry?
Aug 04ProQR Therapeutics: Looks Interesting Ahead Of Next Year's Pivotal Data
Jun 20It's Unlikely That ProQR Therapeutics N.V.'s (NASDAQ:PRQR) CEO Will See A Huge Pay Rise This Year
May 13ProQR Therapeutics offers a de-risked opportunity: Stifel
May 03If You Had Bought ProQR Therapeutics' (NASDAQ:PRQR) Shares A Year Ago You Would Be Down 42%
Mar 08Could The ProQR Therapeutics N.V. (NASDAQ:PRQR) Ownership Structure Tell Us Something Useful?
Feb 01
ProQR concludes enrollment in mid-stage cell therapy trial in a rare eye disorder
Jan 07ProQR Therapeutics (NASDAQ:PRQR) Has Debt But No Earnings; Should You Worry?
Dec 28A Look At ProQR Therapeutics' (NASDAQ:PRQR) Share Price Returns
Dec 01ProQR reports Q3 results
Nov 16Shareholder Returns
| PRQR | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 16.2% | -0.8% | 1.7% |
| 1Y | -47.0% | 4.3% | -9.6% |
Return vs Industry: PRQR underperformed the US Biotechs industry which returned 4.3% over the past year.
Return vs Market: PRQR underperformed the US Market which returned -9.6% over the past year.
Price Volatility
| PRQR volatility | |
|---|---|
| PRQR Average Weekly Movement | 22.8% |
| Biotechs Industry Average Movement | 12.1% |
| Market Average Movement | 6.7% |
| 10% most volatile stocks in US Market | 17.5% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: PRQR is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 23% a week.
Volatility Over Time: PRQR's weekly volatility has increased from 18% to 23% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 182 | Daniel de Boer | https://www.proqr.com |
ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clinical trial to treat USH2A-mediated retinitis pigmentosa and usher syndrome. The company also engages in the developing of Axiomer RNA base-editing platform technology.
ProQR Therapeutics N.V. Fundamentals Summary
| PRQR fundamental statistics | |
|---|---|
| Market Cap | US$225.02m |
| Earnings (TTM) | -US$77.67m |
| Revenue (TTM) | US$4.25m |
53.0x
P/S Ratio-2.9x
P/E RatioIs PRQR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PRQR income statement (TTM) | |
|---|---|
| Revenue | €3.93m |
| Cost of Revenue | €0 |
| Gross Profit | €3.93m |
| Other Expenses | €75.88m |
| Earnings | -€71.94m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.01 |
| Gross Margin | 100.00% |
| Net Profit Margin | -1,829.27% |
| Debt/Equity Ratio | 10.3% |
How did PRQR perform over the long term?
See historical performance and comparison